CoChat

The History and Current State of Antidepressant Clinical Trial Design: A Call to Action for Proof-of-Concept Studies

Gelenberg, Alan J., Thase, Michael E., Meyer, Roger E., Goodwin, Frederick K., Katz, Martin M., Kraemer, Helena Chmura, Potter, William Z., Shelton, Richard C., Fava, Maurizio, Khan, Arif, Trivedi, Madhukar H., Ninan, Philip T., Mann, John J., Bergeson, Susan, Endicott, Jean, Endicott, Jean, Kocsis, James H., Leon, Andrew C., Manji, Husseini K., Rosenbaum, Jerrold F. · 2008 · The Journal of Clinical Psychiatry
Cited by 79

The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.

Abstract

BACKGROUND: The development of new antidepressant drugs has reached a plateau. There is an unmet need for faster, better, and safer medications, but as placebo-response rates rise, effect sizes shrink, and more studies fail or are negative, pharmaceutical companies are increasingly reluctant to invest in new drug development because of the risk of failure. In the absence of an identifiable human pathophysiology that can be modeled in preclinical studies, the principal point of leverage to move beyond the present dilemma may be improving the information gleaned from well-designed proof-of-concept (POC) studies of new antidepressant drugs with novel central nervous system effects. With this in mind, a group of experts was convened under the auspices of the University of Arizona Department of Psychiatry and Best Practice Project Management, Inc. PARTICIPANTS: Forty-five experts in the study of antidepressant drugs from academia, government (U.S. Food and Drug Administration and National Institute of Mental Health), and industry participated. EVIDENCE/CONSENSUS PROCESS: In order to define the state of clinical trials methodology in the antidepressant area, and to chart a way forward, a 2-day consensus conference was held June 21-22, 2007, in Bethesda, Md., at which careful reviews of the literature were presented for discussion. Following the presentations, participants were divided into 3 workgroups and asked to address a series of separate questions related to methodology in POC studies. The goals were to review the history of antidepressant drug trials, discuss ways to improve study design and data analysis, and plan more informative POC studies. CONCLUSIONS: The participants concluded that the federal government, academic centers, and the pharmaceutical industry need to collaborate on establishing a network of sites at which small, POC studies can be conducted and resulting data can be shared. New technologies to analyze and measure the major affective, cognitive, and behavioral components of depression in relationship to potential biomarkers of response should be incorporated. Standard assessment instruments should be employed across studies to allow for future meta-analyses, but new instruments should be developed to differentiate subtypes and symptom clusters within the disorder that might respond differently to treatment. Better early-stage POC studies are needed and should be able to amplify the signal strength of drug efficacy and enhance the quality of information in clinical trials of new medications with novel pharmacologic profiles.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.4088/jcp.v69n1001

Cites

27 of 27 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 27 references

Cited by

See all 79

Metadata

Authors
Gelenberg, A. J., Thase, M. E., Meyer, R. E., Goodwin, F. K., Katz, M. M., Kraemer, H. C., Potter, W. Z., Shelton, R. C., Fava, M., Khan, A., Trivedi, M. H., Ninan, P. T., Mann, J. J., Bergeson, S., Endicott, J., Endicott, J., Kocsis, J. H., Leon, A. C., Manji, H. K., & Rosenbaum, J. F.
Venue
The Journal of Clinical Psychiatry
Published
2008-10-31
Volume
69
Issue
10
Pages
1513-1528
ISSN
0160-6689 (ISSN-L)
OpenAlex
W1976391274
Cited by
79
References
27
FWCI
10.87
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The History and Current State of Antidepressant Clinical Trial Design: A Call to Action for Proof-of-Concept Studies. https://app.cochat.ai/papers/10.4088/jcp.v69n1001
The paper
Gelenberg, A. J., Thase, M. E., Meyer, R. E., Goodwin, F. K., Katz, M. M., Kraemer, H. C., Potter, W. Z., Shelton, R. C., Fava, M., Khan, A., Trivedi, M. H., Ninan, P. T., Mann, J. J., Bergeson, S., Endicott, J., Endicott, J., Kocsis, J. H., Leon, A. C., Manji, H. K., & Rosenbaum, J. F. (2008). The History and Current State of Antidepressant Clinical Trial Design: A Call to Action for Proof-of-Concept Studies. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.v69n1001

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.